Core Viewpoint - ClearPoint Neuro, Inc. (CLPT) shows significant upside potential with a mean price target of $10, indicating an 81.5% increase from the current price of $5.51 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $1, where the lowest estimate of $9 suggests a 63.3% increase, and the highest estimate of $11 indicates a 99.6% surge [2] - A low standard deviation among price targets reflects a high degree of agreement among analysts regarding the stock's price movement [8] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CLPT's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [10] - The Zacks Consensus Estimate for the current year has risen by 16% over the past month, with two estimates increasing and no negative revisions [11] - CLPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [12]

ClearPoint Neuro, Inc. (CLPT) closed the last trading session at $5.86, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10 indicates a 70.7% upside potential. The average comprises three short-term price targets ranging from a low of $9 to a high of $11, with a standard deviation of $1. While the lowest estimate indicates an increase of 53.6% from the current price le ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was $7.6 million, representing a 41% increase from $5.4 million in Q1 2023 [8] - Gross margin remained consistent at 59% for both Q1 2024 and Q1 2023 [12] - Cash and cash equivalents increased to $35.4 million from $23.1 million at the end of 2023, primarily due to a public offering that generated net proceeds of $16.2 million [15][31] - Cash burn in Q1 2024 was $3.8 million, down 32% from the previous year [16] Business Line Data and Key Metrics Changes - Biologics and drug delivery revenue grew 61% to $4.3 million in Q1 2024, up from $2.7 million in Q1 2023 [9] - Functional neurosurgery navigation therapy revenue declined 18% to $1.9 million, attributed to lower service revenue [10] - Capital equipment and software revenue surged 255% to $1.4 million from $0.4 million in the same period last year [11] Market Data and Key Metrics Changes - The company added eight new customers in Q1 2024, a significant increase compared to seven new customers added throughout 2023 [48] - The demand for traditional MRI-guided systems reached an all-time high, contributing to the record capital revenue [48] Company Strategy and Development Direction - The company is focused on a four-pillar growth strategy: biologics and drug delivery, functional neurosurgery navigation, therapy and access products, and achieving global scale [6] - Plans to expand into the operating room and laser therapy, as well as enhance preclinical and clinical trial services [6][30] - The company aims to achieve revenue between $28 million and $32 million for the year, with expectations of double-digit growth across all segments [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in 2024, citing significant progress in financial and strategic goals [19] - The market for neuro biotechnology is showing signs of recovery, with increased capital investment in the sector [25] - The company is well-positioned to benefit from the growing demand for its products and services in neurosurgery [26] Other Important Information - The company achieved FDA clearance for the SmartFrame OR solution, allowing for expanded use of ClearPoint products in operating rooms [27] - The introduction of new software features is expected to enhance the functionality of existing products and support future growth [49] Q&A Session Summary Question: Regarding guidance and strong start to the year - Management indicated that it is too early to change guidance despite a strong Q1, as growth was partly driven by non-recurring capital sales [55] Question: Scale-up process for new customers - Management noted that revenue from new placements is expected to ramp up in Q2, with a potential shift from initial case orders to stocking levels [57] Question: Expansion of product offerings for new customers - It was highlighted that new customers often start with one product but typically expand into additional services and products over time [39][61]

WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdag: CLPT . . © 2024 CLEARPOINT NEURO This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company's expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results. These forward looking statements are based on management's ...

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 FORM 10-Q Or Commission file number: 001-34822 Delaware 58-2394628 (State or Other Jurisdiction (IRS Employer of Incorporation or Organization) Identification Number) (888) 287-9109 (Registrant's Telephone Number, Including Area Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share CLPT Nasdaq Capital M ...

SOLANA BEACH, CA, May 7, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

koto_feja ClearPoint Neuro’s (NASDAQ:CLPT) fourth quarter results were strong, and the first quarter of 2024 is also shaping up well. Despite this, the stock is down significantly over the past 2 months on the back of a sizeable equity raise and interest rate fears. The last time I wrote about ClearPoint I suggested it was a buy, as the company was reasonably valued and approaching an inflection point. This still appears to be the case, with recent developments reducing uncertainty regarding the company ...

SOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner PTC Therapeutics on completion of its BLA submission to the U.S. Food and Drug Administration (FDA) for the approval of Upstaza™ (eladocagene exuparvovec), an investigational treatment for AADC Deficiency. If approved, Upstaza™ would become the first therapy t ...

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Conference Call March 12, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Emily Christy - Stifel William Wood - B. Riley Securities Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Comments made ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.64%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.20, delivering a surprise of 20%.Over the last four quarters, the company has surp ...